117 related articles for article (PubMed ID: 16312547)
1. Pharmacological profile of teicoplanin.
Fraschini F
J Chemother; 1989 Jul; 1(4 Suppl):590-2. PubMed ID: 16312547
[No Abstract] [Full Text] [Related]
2. Evaluation of in vitro activity of teicoplanin against gram-positive anaerobic bacteria.
Anzivino D; Nani E; Gulletta E; Lembo M; Covelli B
J Chemother; 1989 Jul; 1(4 Suppl):201-2. PubMed ID: 16312368
[No Abstract] [Full Text] [Related]
3. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
[TBL] [Abstract][Full Text] [Related]
5. [Teicoplanin. New treatment potentials for gram-positive infections in the hospital].
Iakovlev SV
Antibiot Khimioter; 1999; 44(2):3-7. PubMed ID: 10202550
[No Abstract] [Full Text] [Related]
6. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.
Bowker KE; Noel AR; MacGowan AP
J Antimicrob Chemother; 2006 Oct; 58(4):802-5. PubMed ID: 16891629
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
[TBL] [Abstract][Full Text] [Related]
8. Serum and bone concentrations of teicoplanin and vancomycin: study in an animal model.
Drago L; De Vecchi E; Fassina MC; Gismondo MR
Drugs Exp Clin Res; 1998; 24(4):185-90. PubMed ID: 10051964
[TBL] [Abstract][Full Text] [Related]
9. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
Jones RN; Sader HS; Fritsche TR; Hogan PA; Sheehan DJ
J Clin Microbiol; 2006 Jul; 44(7):2622-5. PubMed ID: 16825398
[TBL] [Abstract][Full Text] [Related]
10. Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives.
Jung HM; Jeya M; Kim SY; Moon HJ; Kumar Singh R; Zhang YW; Lee JK
Appl Microbiol Biotechnol; 2009 Sep; 84(3):417-28. PubMed ID: 19609520
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez HT
Antimicrob Agents Chemother; 2006 Aug; 50(8):2875-9. PubMed ID: 16870792
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.
Fritsche TR; Rennie RP; Goldstein BP; Jones RN
J Clin Microbiol; 2006 Aug; 44(8):2988-90. PubMed ID: 16891523
[TBL] [Abstract][Full Text] [Related]
13. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic efficacy, animal models and experimental pharmacodynamics: what do we know about tigecycline?].
Giménez MJ; Barberán J; Aguilar L
Rev Esp Quimioter; 2007 Dec; 20(4):387-94. PubMed ID: 18563212
[No Abstract] [Full Text] [Related]
15. Dalbavancin: a novel lipoglycopeptide antibacterial.
Pope SD; Roecker AM
Pharmacotherapy; 2006 Jul; 26(7):908-18. PubMed ID: 16803423
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype.
Song JH; Ko KS; Suh JY; Oh WS; Kang CI; Chung DR; Peck KR; Lee NY; Lee WG
J Antimicrob Chemother; 2008 Apr; 61(4):838-44. PubMed ID: 18230690
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration.
Yagasaki K; Gando S; Matsuda N; Kameue T; Ishitani T; Hirano T; Iseki K
Intensive Care Med; 2003 Nov; 29(11):2094-5. PubMed ID: 14504724
[No Abstract] [Full Text] [Related]
18. Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections.
Ogami C; Tsuji Y; Muraki Y; Mizoguchi A; Okuda M; To H
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):175-188. PubMed ID: 30934169
[TBL] [Abstract][Full Text] [Related]
19. Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
Pintér G; Batta G; Kéki S; Mándi A; Komáromi I; Takács-Novák K; Sztaricskai F; Röth E; Ostorházi E; Rozgonyi F; Naesens L; Herczegh P
J Med Chem; 2009 Oct; 52(19):6053-61. PubMed ID: 19791806
[TBL] [Abstract][Full Text] [Related]
20. [Problem of antibiotic therapy of severe infections, due to polyresistant gram-positive microorganisms. Teicoplanin (Targocide): comparative evaluation of antimicrobial activity, clinical importance].
Fomina IP
Antibiot Khimioter; 1999; 44(8):18-22. PubMed ID: 10494386
[No Abstract] [Full Text] [Related]
[Next] [New Search]
